We have established and will continue to selectively establish collaborations with pharmaceutical and diagnostic companies and leading academic institutions to enhance our research, development and commercialization capabilities.
Geron is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
For more information about licensing or partnering opportunities please contact us at CorpDev@geron.com.
We are also interested in evaluating clinical and preclinical product candidates and enabling technologies that fit within our oncology therapeutic focus and complement our corporate and product development strategy.
To submit an opportunity that may meet our in-licensing interests and priorities, please provide a non-confidential overview for our consideration at CorpDev@geron.com.